Collectively, these findings raise the hypothesis that RFX1 acts as an oncogenic transcription factor in colon cancer by shaping an immunosuppressive microenvironment, modulating mutational dynamics, and conferring resistance to immunotherapy. The gene discussed is RFX1; the disease is malignant colon neoplasm.